Overview

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate CancermCRPC

Status:
NOT_YET_RECRUITING

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate the safety, and preliminary antitumor activity of TYK-00540 combined with Enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy

Phase:

PHASE1

Details

Lead Sponsor:

TYK Medicines, Inc

Treatments:

enzalutamide